Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653801 | 0.96 | DRD2 (0.34) | CTSDBACE1DRD2MAOAMAOB | |
| SCHEMBL3652166 | 0.85 | DRD2 (0.34) | CTSDBACE1DRD2MAOAMAOB | |
| SCHEMBL3217314 | 0.85 | DRD2 (0.34) | CTSDBACE1DRD2MAOAMAOB | |
| SCHEMBL3650137 | 0.85 | DRD2 (0.34) | CTSDBACE1DRD2MAOAMAOB | |
| SCHEMBL311003 | 0.77 | DRD2 (0.34) | CTSDBACE1DRD2MAOAMAOB | |
| SCHEMBL3649307 | 0.75 | BACE1 (0.57) | CTSDBACE1 | |
| Hydrochloric Acid SCHEMBL3644876 | 0.73 | ATM (0.40) | — | |
| SCHEMBL3646307 | 0.71 | DRD2 (0.31) | DRD2 | |
| SCHEMBL310719 | 0.70 | CTSD (0.39) | CTSDBACE1DRD2 | |
| SCHEMBL3649709 | 0.70 | BACE1 (0.43) | CTSDBACE1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | CTSD 38/4885BACE1 2/4885DRD2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.